38 related articles for article (PubMed ID: 350397)
1. Intrapleural and intravenous Corynebacterium parvum in patients with resected stage I and II non-small cell carcinoma of the lung. The Ludwig Lung Cancer Study Group.
Ludwig Lung Cancer Study Group
Cancer Immunol Immunother; 1986; 23(1):1-4. PubMed ID: 2876772
[TBL] [Abstract][Full Text] [Related]
2. A phase-II trial of Corynebacterium parvum as adjuvant to surgery in the treatment of operable lung cancer.
Woodruff M; Walbaum P
Cancer Immunol Immunother; 1983; 16(2):114-6. PubMed ID: 6362846
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy.
Parodi AL; Misdorp W; Mialot JP; Mialot M; Hart AA; Hurtrel M; Salomon JC
Cancer Immunol Immunother; 1983; 15(3):172-7. PubMed ID: 6555059
[TBL] [Abstract][Full Text] [Related]
4. Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma.
Liberati AM; Voelkel JG; Borden EC; Coates AS; Citrin DL; Bryan GT
Cancer Immunol Immunother; 1982; 13(2):140-4. PubMed ID: 6961952
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B plus combination chemotherapy for extensive non-small cell bronchogenic carcinoma.
Sarna G; Lowitz BB; Ganz PA; Cline MJ
Cancer Chemother Pharmacol; 1980; 5(2):89-92. PubMed ID: 7471319
[TBL] [Abstract][Full Text] [Related]
6. Corynebacterium parvum and metastatic breast cancer.
Haskell CM; Sarna GP; Liu PY
Br J Cancer; 1982 May; 45(5):794-5. PubMed ID: 7044404
[No Abstract] [Full Text] [Related]
7. Effects of BCG and 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) on the cytostatic activity of macrophages in normal and tumour-bearing rats.
Saijo N; Irimajiri N; Ozaki A; Shimizu E; Niitani H
Br J Cancer; 1980 Jul; 42(1):162-7. PubMed ID: 7000114
[No Abstract] [Full Text] [Related]
8. Gallium-67 citrate imaging for the assessment of radiation pneumonitis.
Kataoka M
Ann Nucl Med; 1989 Jul; 3(2):73-81. PubMed ID: 2641451
[TBL] [Abstract][Full Text] [Related]
9. The treatment of lung cancer.
Zubrod CG; Selawry O
Adv Intern Med; 1978; 23():451-67. PubMed ID: 204171
[No Abstract] [Full Text] [Related]
10. Chemo-immunotherapy for unresectable bronchogenic carcinoma.
Sarna GP; Lowitz BB; Haskell CM; Dorey FJ; Cline MJ
Cancer Treat Rep; 1978 May; 62(5):681-7. PubMed ID: 350397
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin, cisplatin, and Corynebacterium parvum in non-small cell bronchogenic carcinoma.
Drapkin R; Bjornsson S; Naeher C; Higby D; Caracandas J; Wallens WT; Kuberka N; Suh K; Siddiqi N; Henderson ES
Cancer Treat Rep; 1980; 64(12):1367-9. PubMed ID: 7193520
[TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy in 34 cases of oat cell carcinoma of the lung with 19 complete responses.
Israël L; Depierre A; Choffel C; Milleron B; Edelstein R
Cancer Treat Rep; 1977; 61(3):343-7. PubMed ID: 68827
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
